Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome–positive acute lymphoblastic leukemia
- 1 September 2014
- journal article
- research article
- Published by Elsevier BV in Cytotherapy
- Vol. 16 (9), 1257-1269
- https://doi.org/10.1016/j.jcyt.2014.05.022
Abstract
No abstract availableKeywords
Funding Information
- JSPS KAKENHI (23591533, 24791050, 26461574)
- Takeda Science Foundation
- Japan Leukemia Research Fund
This publication has 31 references indexed in Scilit:
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive LeukemiasThe New England Journal of Medicine, 2013
- piggyBac Transposon System Modification of Primary Human T CellsJournal of Visualized Experiments, 2012
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasBlood, 2011
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood, 2010
- How I treat Philadelphia chromosome–positive acute lymphoblastic leukemiaBlood, 2010
- piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage MalignanciesHuman Gene Therapy, 2010
- Optimization of the PiggyBac Transposon System for the Sustained Genetic Modification of Human T LymphocytesJournal of Immunotherapy, 2009
- KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocationBlood, 2009
- Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitorLeukemia Research, 2009
- Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid LeukemiaClinical Cancer Research, 2006